首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷 CT/MRI/X光

全球 PET 放射性示踪劑市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1332696

全球 PET 放射性示踪劑市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global PET Radiotracer Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球 PET 放射性示踪劑市場的市場規模將從 2022 年的 31.7 億美元達到近 64 億美元，2023-2030 年研究期間年複合成長率為 9.2%。

PET放射性示踪劑，也稱為PET放射性藥物或PET示踪劑，是一種用於正電子發射斷層掃描（PET）成像的放射性化合物。它是一種核成像技術，可提供體內生理和生化過程的詳細圖像。

市場動態：

全球範圍內癌症患病率的不斷上升推動了對放射性示踪劑 PET 成像的需求，這有助於癌症診斷和治療評估。分子成像的進步和新型放射性示踪劑的開發擴展了 PET 成像的能力，使其適用於各種醫學領域和生理過程。對早期疾病檢測和個性化醫療的重視進一步推動了對 PET 放射性示踪劑的需求。核醫學的研究和開發工作導致了新型放射性示踪劑的發現，增強了 PET 成像的可用性和應用。資金、投資和政府支持的增加促進了 PET 放射性示踪劑的商業化和採用。人口老齡化的不斷成長增加了對癌症和神經退行性疾病等與年齡相關的疾病的 PET 成像的需求。 PET 放射性示踪劑在藥物開發和臨床試驗、評估藥物療效和靶點參與方面也至關重要。有利的報銷政策以及 PET 與其他成像方式的整合進一步支持了 PET 放射性示踪劑市場的成長。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球寵物放射性示踪劑市場的各個細分市場進行了包容性評估。寵物放射性示踪劑行業的成長和趨勢為這項研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 PET 放射性示踪劑市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 PET放射性示踪劑市場的主要參與者包括ABX先進生化化合物有限公司（劍橋同位素實驗室公司）、Blue Earth Diagnostics、Cardinal Health.、禮來公司、GE Healthcare、IBA Radiopharma Solutions、Jubilant Pharma Limited、Lantheus Holdings Inc。、西門子Healthineers AG、煙台東誠藥業Group Limited。本部分包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史和預測數據銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史和預測數據銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：寵物放射示踪劑公司的競爭格局

寵物放射性示踪劑市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)

公司簡介
公司收入
產品
最近的發展

Blue Earth Diagnostics

公司簡介
公司收入
產品
最近的發展

Cardinal Health.

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

GE Healthcare

公司簡介
公司收入
產品
最近的發展

IBA Radiopharma Solutions

公司簡介
公司收入
產品
最近的發展

Jubilant Pharma Limited

公司簡介
公司收入
產品
最近的發展

Lantheus Holdings Inc.

公司簡介
公司收入
產品
最近的發展

Siemens Healthineers AG

公司簡介
公司收入
產品
最近的發展

Yantai Dungcheng Pharmaceutical Group Co. Ltd.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112111873

The global demand for PET Radiotracer Market is presumed to reach the market size of nearly USD 6.4 BN by 2030 from USD 3.17 BN in 2022 with a CAGR of 9.2% under the study period 2023 - 2030.

A PET radiotracer, also known as a PET radiopharmaceutical or PET tracer, is a radioactive compound used in Positron Emission Tomography (PET) imaging.It is a nuclear imaging technique that provides detailed images of the physiological and biochemical processes in the body.

MARKET DYNAMICS:

The increasing prevalence of cancer worldwide fuels the demand for PET imaging with radiotracers, which assist in cancer diagnosis and treatment evaluation. Advancements in molecular imaging and the development of new radiotracers expand the capabilities of PET imaging, making it applicable to various medical fields and physiological processes. The emphasis on early disease detection and personalized medicine further drives the demand for PET radiotracers. Research and development efforts in nuclear medicine result in the discovery of novel radiotracers, enhancing the availability and application of PET imaging. Increased funding, investments, and government support boost the commercialization and adoption of PET radiotracers. The growing ageing population contributes to the demand for PET imaging in age-related diseases, such as cancer and neurodegenerative disorders. PET radiotracers are also essential in drug development and clinical trials, assessing drug efficacy and target engagement. Favourable reimbursement policies and the integration of PET with other imaging modalities further support the growth of the PET radiotracer market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pet radiotracer. The growth and trends of pet radiotracer industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pet radiotracer market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Radiotracer Type

F-18 (FDG18)
Ga 68 (FAPI)
Others

By Application

Cancer
Heart Disease
Gastrointestinal
Endocrine
Neurological Disorders
Others

By End-User

Hospitals
Diagnostic Centers
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the PET Radiotracer market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PET Radiotracer market include ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.), Blue Earth Diagnostics, Cardinal Health., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc., Siemens Healthineers AG, Yantai Dungcheng Pharmaceutical Group Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PET RADIOTRACER - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Radiotracer Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY RADIOTRACER TYPE

5.1 Overview by Radiotracer Type
5.2 Historical and Forecast Data
5.3 Analysis by Radiotracer Type
5.4 F-18 (FDG18) Historic and Forecast Sales by Regions
5.5 Ga 68 (FAPI) Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Cancer Historic and Forecast Sales by Regions
6.5 Heart Disease Historic and Forecast Sales by Regions
6.6 Gastrointestinal Historic and Forecast Sales by Regions
6.7 Endocrine Historic and Forecast Sales by Regions
6.8 Neurological Disorders Historic and Forecast Sales by Regions
6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY END-USER

7.1 Overview by End-user
7.2 Historical and Forecast Data
7.3 Analysis by End-user
7.4 Hospitals Historic and Forecast Sales by Regions
7.5 Diagnostic Centers Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PET RADIOTRACER COMPANIES

9.1. Pet Radiotracer Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF PET RADIOTRACER INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Blue Earth Diagnostics
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Cardinal Health.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Eli Lilly and Company
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. GE Healthcare
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. IBA Radiopharma Solutions
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Jubilant Pharma Limited
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Lantheus Holdings Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Siemens Healthineers AG
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Yantai Dungcheng Pharmaceutical Group Co. Ltd.
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments